2016•Unpublished venueRequires access
Recent progress of myelodysplastic syndromes
Min Lin
Open publisher page 0 citations
Abstract
The myelodysplastic syndromes(MDS), which are characterized by the presence of ineffective hematopoiesis and an increased risk of transformation into acute myeloid leukemia(AML), are a group of clonal disorders deriving from damage of the hematopoietic stem/progenitor cells. Researches in the past few years have still highly recommended the pathogenesis, clinical new agents and combination therapy,immunotherapy and hematopoietic stem cell transplantation of the MDS. This article will introduce several highlights of MDS combined with the relevant reports in the 57th American Society of Hematology annual meeting.
Key words:
Myelodysplastic syndromes; Pathogenesis; Somatic mutation; Azacitidine; Hypomethylating agents